133 related articles for article (PubMed ID: 34942386)
1. MiRNA-181d Expression Correlates in Tumor versus Plasma of Glioblastoma Patients-the Base of a Preoperative Stratification Tool for Local Carmustine Wafer Use.
Sippl C; Quiring A; Teping F; Schulz-Schaeffer W; Urbschat S; Ketter R; Oertel J
World Neurosurg; 2022 Mar; 159():e324-e333. PubMed ID: 34942386
[TBL] [Abstract][Full Text] [Related]
2. MiRNA-181d Expression Significantly Affects Treatment Responses to Carmustine Wafer Implantation.
Sippl C; Ketter R; Bohr L; Kim YJ; List M; Oertel J; Urbschat S
Neurosurgery; 2019 Jul; 85(1):147-155. PubMed ID: 29846701
[TBL] [Abstract][Full Text] [Related]
3. miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme.
Sippl C; Ketter R; Braun L; Teping F; Schoeneberger L; Kim YJ; List M; Nakhoda A; Wemmert S; Oertel J; Urbschat S
Acta Neurochir (Wien); 2019 Nov; 161(11):2299-2309. PubMed ID: 31478117
[TBL] [Abstract][Full Text] [Related]
4. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression.
Zhang W; Zhang J; Hoadley K; Kushwaha D; Ramakrishnan V; Li S; Kang C; You Y; Jiang C; Song SW; Jiang T; Chen CC
Neuro Oncol; 2012 Jun; 14(6):712-9. PubMed ID: 22570426
[TBL] [Abstract][Full Text] [Related]
5. miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma.
Khalil S; Fabbri E; Santangelo A; Bezzerri V; Cantù C; Di Gennaro G; Finotti A; Ghimenton C; Eccher A; Dechecchi M; Scarpa A; Hirshman B; Chen C; Ferracin M; Negrini M; Gambari R; Cabrini G
Oncotarget; 2016 May; 7(19):28195-206. PubMed ID: 27057640
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
7. microRNA-181a mediates the chemo-sensitivity of glioblastoma to carmustine and regulates cell proliferation, migration, and apoptosis.
Rezaei T; Hejazi M; Mansoori B; Mohammadi A; Amini M; Mosafer J; Rezaei S; Mokhtarzadeh A; Baradaran B
Eur J Pharmacol; 2020 Dec; 888():173483. PubMed ID: 32810491
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
Pallud J; Audureau E; Noel G; Corns R; Lechapt-Zalcman E; Duntze J; Pavlov V; Guyotat J; Hieu PD; Le Reste PJ; Faillot T; Litre CF; Desse N; Petit A; Emery E; Voirin J; Peltier J; Caire F; Vignes JR; Barat JL; Langlois O; Dezamis E; Parraga E; Zanello M; Nader E; Lefranc M; Bauchet L; Devaux B; Menei P; Metellus P;
Neuro Oncol; 2015 Dec; 17(12):1609-19. PubMed ID: 26185110
[TBL] [Abstract][Full Text] [Related]
9. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
10. The intra-tumoral heterogeneity in glioblastoma - a limitation for prognostic value of epigenetic markers?
Christoph S; Alicia S; Fritz T; Vanessa T; Ralf K; Jin KY; Stefan L; Joachim O
Acta Neurochir (Wien); 2023 Jun; 165(6):1635-1644. PubMed ID: 37083881
[TBL] [Abstract][Full Text] [Related]
11. Ventricular opening and cerebrospinal fluid circulation accelerate the biodegradation process of carmustine wafers suggesting their immunomodulation potential in the human brain.
Shibahara I; Shibahara Y; Hagiwara H; Watanabe T; Orihashi Y; Handa H; Inukai M; Hide T; Yasui Y; Kumabe T
J Neurooncol; 2022 Sep; 159(2):425-435. PubMed ID: 35802230
[TBL] [Abstract][Full Text] [Related]
12. Carmustine wafer implantation for supratentorial glioblastomas, IDH-wildtype in "extreme" neurosurgical conditions.
Roux A; Aboubakr O; Elia A; Moiraghi A; Benevello C; Fathallah H; Parraga E; Oppenheim C; Chretien F; Dezamis E; Zanello M; Pallud J
Neurosurg Rev; 2023 Jun; 46(1):140. PubMed ID: 37329341
[TBL] [Abstract][Full Text] [Related]
13. Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice.
Roux A; Peeters S; Zanello M; Bou Nassif R; Abi Lahoud G; Dezamis E; Parraga E; Lechapt-Zalcmann E; Dhermain F; Dumont S; Louvel G; Chretien F; Sauvageon X; Devaux B; Oppenheim C; Pallud J
J Neurooncol; 2017 Oct; 135(1):83-92. PubMed ID: 28669011
[TBL] [Abstract][Full Text] [Related]
14. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series.
Subach BR; Witham TF; Kondziolka D; Lunsford LD; Bozik M; Schiff D
Neurosurgery; 1999 Jul; 45(1):17-22; discussion 22-3. PubMed ID: 10414561
[TBL] [Abstract][Full Text] [Related]
15. The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema.
Hasegawa Y; Iuchi T; Sakaida T; Yokoi S; Kawasaki K
J Clin Neurosci; 2016 Sep; 31():67-71. PubMed ID: 27430412
[TBL] [Abstract][Full Text] [Related]
16. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.
Giese A; Kucinski T; Knopp U; Goldbrunner R; Hamel W; Mehdorn HM; Tonn JC; Hilt D; Westphal M
J Neurooncol; 2004 Feb; 66(3):351-60. PubMed ID: 15015668
[TBL] [Abstract][Full Text] [Related]
17. miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF-κB pathways in glioblastoma.
Yang F; Liu X; Liu Y; Liu Y; Zhang C; Wang Z; Jiang T; Wang Y
Cancer Lett; 2017 Jun; 396():1-9. PubMed ID: 28286260
[TBL] [Abstract][Full Text] [Related]
18. Identification of IGF-1-enhanced cytokine expressions targeted by miR-181d in glioblastomas via an integrative miRNA/mRNA regulatory network analysis.
Ho KH; Chen PH; Hsi E; Shih CM; Chang WC; Cheng CH; Lin CW; Chen KC
Sci Rep; 2017 Apr; 7(1):732. PubMed ID: 28389653
[TBL] [Abstract][Full Text] [Related]
19. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
